Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Operating Leases: 2021-2025

Historic Operating Leases for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Sep 2025 value amounting to $3.5 million.

  • Rhythm Pharmaceuticals' Operating Leases fell 12.78% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 12.78%. This contributed to the annual value of $3.9 million for FY2024, which is 703.67% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Operating Leases of $3.5 million as of Q3 2025, which was down 4.51% from $3.7 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Operating Leases high stood at $4.0 million for Q3 2024, and its period low was $284,000 during Q1 2024.
  • Its 3-year average for Operating Leases is $2.3 million, with a median of $3.3 million in 2024.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Operating Leases tumbled by 73.61% in 2024, and later spiked by 1,251.76% in 2025.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Operating Leases stood at $1.9 million in 2021, then plummeted by 35.22% to $1.3 million in 2022, then plummeted by 61.11% to $490,000 in 2023, then spiked by 703.67% to $3.9 million in 2024, then fell by 12.78% to $3.5 million in 2025.
  • Its Operating Leases stands at $3.5 million for Q3 2025, versus $3.7 million for Q2 2025 and $3.8 million for Q1 2025.